Izhar Salomon
Ph.D. Student
Department of Cancer
Netherlands Cancer Institute
Netherlands
Biography
He joined the Linn group in 2012 with a strong background in immunology/cell biology at the NKI. Tamoxifen, an antagonist of the Estrogen Receptor (ER) is a common treatment for ER positive breast cancer. Additionally, it has been shown to be a modulator of immune cells. He was involved in a project that studies the role of the immune system in breast cancer outcome and whether certain tumor immune cell infiltrates affect adjuvant tamoxifen efficacy. Additionally they study lymphocytes from healthy donors, and determine whether tamoxifen induces a different ER binding landscape in lymphocytes.
Research Interest
Immunology and Cell Biology
